Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded indication and increased use of Immune checkpoint inhibitors have resulted in increased reports of...
Main Authors: | Zherui Liu, Yun Zhu, Huan Xie, Zhengsheng Zou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1077468/full |
Similar Items
-
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
by: J. Randall Patrinely, et al.
Published: (2021-01-01) -
Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology
by: Julian Hercun, et al.
Published: (2022-06-01) -
Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01) -
Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01) -
Efficacy and safety of mycophenolate mofetil in treating immune‐related hepatitis induced by immune checkpoint inhibitor use: A retrospective study
by: Yukio Kadokawa, et al.
Published: (2023-02-01)